QIAGEN's QIAstat-Dx Meningitis/Encephalitis Panel, a qualitative multiplexed nucleic acid-based in vitro diagnostic test has received approval from the Health Sciences Authority Singapore (HSA).

With the introduction of new syndromic testing for central nervous system infections, QIAGEN expands its QIAstat-Dx syndromic testing menu, complementing it with QIAstat-Dx Respiratory SARS-CoV-2 Panel and QIAstat-Dx Gastrointestinal Panel in Singapore. QIAstat-Dx Meningitis/Encephalitis Panel of QIAGEN is designed to meet an urgent need for rapid and reliable diagnosis of these infections and will enable clinicians to select appropriate therapies in a timely manner. 

The Panel analyzes 15 viral bacterial and fungal pathogens in patients with suspected central nervous  system infections simultaneously and provides results in just 80 minutes, enabling clinicians to select  appropriate therapies in a timely manner. The test boasts high sensitivity and specificity, addressing an
urgent need for rapid and reliable diagnosis of these life-threatening infections.

Syndromic testing uses multiplexed real-time polymerase chain reaction (PCR) to analyze multiple pathogens simultaneously in a small patient sample. Doing so helps doctors accurately diagnose patients presenting with many overlapping symptoms.

The QIAstat-Dx system is formulated for use in laboratories and employs cost-efficient, single-use cartridges with all reagents on board and built-in sample processing. Utilizing multiplex real-time PCR, it detects and differentiates between multiple pathogens. QIAstat-Dx additionally provides easy-to-view cycle threshold (Ct) values and amplification curves that can offer additional insights not available with end-point PCR or other techniques.